---
schema_version: "secwatch.filing_event.v1"
accession: "0001819790-23-000028"
form_type: "8-K"
ticker: "TARS"
cik: "0001819790"
company_name: "Tarsus Pharmaceuticals, Inc."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T09:47:30.816569+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tarsus Q1 net loss $23.4M; cash $201.2M; TP-03 PDUFA Aug 25

## Summary
- Net loss of $23.4M vs $20.2M in Q1 2022; revenue $2.5M from LianBio partnership.
- Cash and marketable securities $201.2M as of March 31, 2023.
- TP-03 (Demodex blepharitis) PDUFA date August 25, 2023; 93% of eye doctors would prescribe if approved.
- Phase 2a trials ongoing for TP-04 (rosacea), TP-05 (Lyme prevention), and TP-03 (MGD).
- Appointed Jeff Farrow as CFO and Chief Strategy Officer.

## SEC filing metadata
- accession: 0001819790-23-000028
- form_type: 8-K
- ticker: TARS
- cik: 0001819790
- company_name: Tarsus Pharmaceuticals, Inc.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819790/000181979023000028/0001819790-23-000028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819790/000181979023000028/tars-20230509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001819790-23-000028
- JSON: https://secwatch.observer/filing/0001819790-23-000028.json
- Plain text: https://secwatch.observer/filing/0001819790-23-000028.txt

## Key facts
- Earnings Releases
  Tarsus Pharmaceuticals, Inc. reported financial results for the first quarter ended March 31, 2023.
  - Period: the first quarter ended March 31, 2023
  - Result: reported results
  source text: Tarsus Pharmaceuticals, Inc. (the “Company”) issued a press release, which, among other matters, sets forth the Company’s results of operations for the three months ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819790/000181979023000028/0001819790-23-000028-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.